📈 Stocks

RadNet Q2 Revenue Surges 25% to $622.7M; Updates FY2026 Guidance

RadNet Q2 2026 revenue jumps 25% to a record $622.7M, but the company warns of a wider H1 net loss as Digital Health investments and interest costs pressure bottom-line results.

🕐 1 min read

1 assets impacted (Crypto). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: RDNT → 6/10 (85% confidence).

📊 Affected Assets (1)

RDNT
Neutral 🤖 85%
📆 Mid-term 🌍 US · Explicit

RadNet's record Q2 revenue and raised full-year guidance suggest the core imaging business fundamentals remain strong despite profitability headwinds. The 25% revenue jump, 238 bps mix shift to advanced imaging, and 21% procedural growth may attract growth investors, but the widened six-month net loss, lower adjusted EPS, and dilution from share count growth are clear profit-related drags.

Catalysts
  • Q2 revenue up 25% to $622.7M with raised FY2026 revenue and adjusted EBITDA guidance—signals continued growth
  • Advanced imaging volume and mix improvement (29.9% of volume, up 238 bps) support revenue per scan
Risk Factors
  • Full-year net loss widened to $25.9M and adjusted EPS declined 14.7% YoY, raising concerns about cash conversion
  • Rising interest expense guidance, equity dilution (share count up 4.2%), and hedge fund ownership declining from 30 to 22 funds
▼ Show FAQ (1) ▲ Hide FAQ
Why is RadNet's stock up despite the wider net loss?

The market is likely focusing on the better-than-expected revenue growth, record quarterly revenue, and raised full-year EBITDA guidance rather than one-off charges like acquisition costs and debt refinancing losses.

🎯 Key Takeaways

  • Q2 revenue rose 25% YoY to $622.7M, a record, led by advanced imaging volume growth and a mix shift toward higher-reimbursement procedures.
  • Adjusted EPS declined to $0.29 from $0.34 a year earlier; six-month net loss widened to $25.9M despite revenue growth.
  • Digital Health revenue surged to $32.4M (+61% YoY) and ARR nearly doubled to $105.5M, but segment EBITDA fell 27.2% amid heavy sales/marketing spend.
  • RadNet trimmed the high end of FY2026 revenue guidance, now $2.37B–$2.42B, and raised adjusted EBITDA to $358M–$370M.
  • AI-related imaging mix and hospital JV partnerships continue to expand, with 157 imaging centers now in health system JVs.

📝 Executive Summary

RadNet's Q2 2026 revenue climbed 25% to $622.7M with advanced imaging mix improving to 29.9% of volumes she pushed Imaging Center EBITDA margins to 16.1%. However, adjusted EPS fell to $0.29 from $0.34 and H1 net loss widened to $25.5M, masking the record top-line performance. Digital Health ARR nearly doubled to $105.5M, but segment EBITDA dropped as the company invests in commercialization; hedge fund positions also trimmed 30% during the quarter.

❓ FAQ

Why did RadNet's stock react positively despite a wider net loss?

Investors focused on record revenue and raised guidance rather than the $25.9M H1 loss driven by acquisition costs, debt refinancing, and amortization. Hedge fund holdings dropped from 30 to 22 funds, but ARR growth in Digital Health created longer-term optimism.

What is driving RadNet's Digital Health revenue growth?

ARR increased from $53.5M at June 30, 2025 to $105.5M by June 30, 2026 — a 97% jump. External customers now account for a growing share of that revenue, contributing to the segment's 56.5% YoY growth.